Advertisement
Screener

ABEONA THERAPEUTICS INC. (ABEO) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

ABEONA THERAPEUTICS INC. Financing Cash Flow

ABEONA THERAPEUTICS INC. (ABEO) reported Financing Cash Flow of -$5.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13

  • ABEONA THERAPEUTICS INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$3.33M, a 131.78% decline year-over-year.
  • ABEONA THERAPEUTICS INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$2.22M, a 132.83% decline year-over-year.
  • ABEONA THERAPEUTICS INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $3.61M, a 31.99% decline year-over-year.
  • ABEONA THERAPEUTICS INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $5.16M.
  • ABEONA THERAPEUTICS INC. net cash provided by (used in) financing activities for fiscal 2025 was $26.04M, a 74.99% decline from fiscal 2024.
  • ABEONA THERAPEUTICS INC. net cash provided by (used in) financing activities for fiscal 2024 was $104.14M, a 181.02% increase from fiscal 2023.
  • ABEONA THERAPEUTICS INC. net cash provided by (used in) financing activities for fiscal 2023 was $37.06M, a 14.17% decline from fiscal 2022.
  • ABEONA THERAPEUTICS INC. net cash provided by (used in) financing activities for fiscal 2022 was $43.17M, a 73.66% increase from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-06-30-$3.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$5.56M
10-Q · filed 2026-08-13
-$1.94M
derived: sum of 3 quarters · filed 2026-08-13
$3.22M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31-$2.22M
10-Q · filed 2026-05-13
$1.39M
derived: sum of 2 quarters · filed 2026-05-13
$6.55M
derived: sum of 3 quarters · filed 2026-05-13
$17.05M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$3.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17
$8.78M
derived: sum of 2 quarters · filed 2026-03-17
$19.27M
derived: sum of 3 quarters · filed 2026-08-13
$26.04M
10-K · filed 2026-03-17
2025-09-30$5.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$15.66M
derived: sum of 2 quarters · filed 2026-08-13
$22.43M
10-Q · filed 2025-11-12
$27.74M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$10.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$17.26M
10-Q · filed 2026-08-13
$22.58M
derived: sum of 3 quarters · filed 2026-08-13
$22.28M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$6.77M
10-Q · filed 2026-05-13
$12.08M
derived: sum of 2 quarters · filed 2026-05-13
$11.78M
derived: sum of 3 quarters · filed 2026-05-13
$85.47M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$5.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17
$5.01M
derived: sum of 2 quarters · filed 2026-03-17
$78.70M
derived: sum of 3 quarters · filed 2026-03-17
$104.14M
10-K · filed 2026-03-17
2024-09-30-$299.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$73.39M
derived: sum of 2 quarters · filed 2025-11-12
$98.83M
10-Q · filed 2025-11-12
$106.29M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$73.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$99.12M
10-Q · filed 2025-08-14
$106.59M
derived: sum of 3 quarters · filed 2025-08-14
$129.57M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$25.44M
10-Q · filed 2025-05-15
$32.91M
derived: sum of 2 quarters · filed 2025-05-15
$55.88M
derived: sum of 3 quarters · filed 2025-05-15
$62.50M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31$7.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
$30.44M
derived: sum of 2 quarters · filed 2025-03-20
$37.06M
derived: sum of 3 quarters · filed 2025-03-20
$37.06M
10-K · filed 2025-03-20
2023-09-30$22.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$29.59M
derived: sum of 2 quarters · filed 2024-11-14
$29.59M
10-Q · filed 2024-11-14
$72.36M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$6.62M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
$6.61M
10-Q · filed 2024-08-12
$49.38M
derived: sum of 3 quarters · filed 2024-08-12
$53.57M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$4.00K
10-Q · filed 2024-05-15
$42.76M
derived: sum of 2 quarters · filed 2024-05-15
$46.95M
derived: sum of 3 quarters · filed 2024-05-15
2022-12-31$42.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
$46.95M
derived: sum of 2 quarters · filed 2024-03-18
$43.17M
10-K · filed 2024-03-18
2022-09-30$4.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
$407.00K
10-Q · filed 2023-11-13
2022-06-30-$3.78M
10-Q · filed 2023-08-08
2021-12-31$16.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29
$16.50M
derived: sum of 2 quarters · filed 2023-03-29
$18.98M
derived: sum of 3 quarters · filed 2023-03-29
$24.86M
10-K · filed 2023-03-29
2021-09-30$173.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$2.65M
derived: sum of 2 quarters · filed 2022-11-14
$8.53M
10-Q · filed 2022-11-14
$8.53M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$2.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$8.36M
10-Q · filed 2022-08-11
$8.36M
derived: sum of 3 quarters · filed 2022-08-11
$8.36M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31$5.88M
10-Q · filed 2022-05-13
$5.88M
derived: sum of 2 quarters · filed 2022-05-13
$5.88M
derived: sum of 3 quarters · filed 2022-05-13
2020-12-31$3.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$3.00K
derived: sum of 2 quarters · filed 2022-03-31
$1.94M
10-K · filed 2022-03-31
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$1.93M
10-Q · filed 2021-11-15
2020-06-30$1.93M
10-Q · filed 2021-07-28
2019-12-31$96.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24
$100.87M
derived: sum of 2 quarters · filed 2021-03-24
$113.87M
derived: sum of 3 quarters · filed 2021-03-24
$113.90M
10-K · filed 2021-03-24
2019-09-30$4.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$17.35M
derived: sum of 2 quarters · filed 2020-11-09
$17.38M
10-Q · filed 2020-11-09
$17.37M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30$13.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$13.04M
10-Q · filed 2020-08-10
$13.03M
derived: sum of 3 quarters · filed 2020-08-10
$16.11M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31$28.00K
10-Q · filed 2020-05-06
$27.00K
derived: sum of 2 quarters · filed 2020-05-06
$3.11M
derived: sum of 3 quarters · filed 2020-05-06
$3.68M
derived: sum of 4 quarters · filed 2020-05-06
2018-12-31-$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
$3.08M
derived: sum of 2 quarters · filed 2020-03-16
$3.65M
derived: sum of 3 quarters · filed 2020-03-16
$5.48M
10-K · filed 2020-03-16
2018-09-30$3.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$3.65M
derived: sum of 2 quarters · filed 2019-11-12
$5.48M
10-Q · filed 2019-11-12
$92.74M
derived: sum of 4 quarters · filed 2020-03-16
2018-06-30$570.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$2.40M
10-Q · filed 2019-08-09
$89.66M
derived: sum of 3 quarters · filed 2020-03-16
$94.72M
derived: sum of 4 quarters · filed 2020-03-16
2018-03-31$1.83M
10-Q · filed 2019-05-10
$89.09M
derived: sum of 2 quarters · filed 2020-03-16
$94.15M
derived: sum of 3 quarters · filed 2020-03-16
$94.23M
derived: sum of 4 quarters · filed 2020-03-16
2017-12-31$87.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
$92.32M
derived: sum of 2 quarters · filed 2020-03-16
$92.40M
derived: sum of 3 quarters · filed 2020-03-16
$92.40M
10-K · filed 2020-03-16
2017-09-30$5.06M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$5.14M
derived: sum of 2 quarters · filed 2018-11-09
$5.14M
10-Q · filed 2018-11-09
$46.51M
derived: sum of 4 quarters · filed 2019-03-18
2017-06-30$84.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$85.00K
10-Q · filed 2018-08-09
$41.45M
derived: sum of 3 quarters · filed 2019-03-18
2017-03-31$1.00K
10-Q · filed 2018-05-10
$41.37M
derived: sum of 2 quarters · filed 2019-03-18
2016-12-31$41.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
$42.54M
10-K · filed 2019-03-18
2016-09-30$1.17M
10-Q · filed 2017-11-14
2014-09-30$250.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14
$250.00K
10-Q · filed 2014-11-14
2014-06-30$0.00
10-Q · filed 2014-08-14
2013-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26
$18.00K
derived: sum of 2 quarters · filed 2014-11-14
$29.00K
10-K · filed 2014-03-26
2013-09-30$18.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14
$29.00K
10-Q · filed 2014-11-14
2013-06-30$11.00K
10-Q · filed 2014-08-14
2012-12-31$1.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26
$1.90M
derived: sum of 2 quarters · filed 2014-03-26
$1.90M
10-K · filed 2014-03-26
2012-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14
$0.00
10-Q · filed 2013-11-14
2012-06-30$0.00
10-Q · filed 2013-08-14
2011-12-31$3.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-20
$3.08M
derived: sum of 2 quarters · filed 2013-03-20
$3.08M
10-K · filed 2013-03-20
2011-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14
$0.00
10-Q · filed 2011-11-14
2011-06-30$0.00
10-Q · filed 2011-08-15
2010-12-31$7.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-23
$7.30M
derived: sum of 2 quarters · filed 2012-03-23
$13.29M
10-K · filed 2012-03-23
2010-09-30$52.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14
$6.04M
10-Q · filed 2011-11-14
2010-06-30$5.99M
10-Q · filed 2011-08-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Evommune, Inc. (EVMN)United States$0.320B-5.10
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
STANDARD BIOTOOLS INC. (LAB)United States$0.297B3.80
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40